Imugene CEO Leslie Chong joins Proactive to reflect on a milestone-filled 2025, headlined by azer-cel’s 82% response rate in CAR T relapsed/refractory DLBCL patients and 83% in CAR T naïve lymphomas.
Chong also outlines positive FDA feedback supporting Imugene’s pivotal trial plans and manufacturing strategy for azer-cel, along with a new onCARlytics collaboration in China to expand into solid tumours.
Heading into 2026, Imugene will focus on trial execution, business development, and serving under-treated cancer populations with its allogeneic CAR-T approach.
#Imugene #BiotechNews #Azer_cel #CancerResearch #FDAApproval #LymphomaTreatment #AllogeneicCAR_T #Immunotherapy #BiotechUpdates #ProactiveInvestors